Twist Bioscience Price to Free Cash Flow Ratio 2017-2021 | TWST

Historical price to free cash flow ratio values for Twist Bioscience (TWST) since 2017. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Twist Bioscience Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 112.80 0.00
2021-06-30 133.25 $-2.87 0.00
2021-03-31 123.86 $-2.50 0.00
2020-12-31 141.29 $-3.38 0.00
2020-09-30 75.97 $-3.88 0.00
2020-06-30 45.30 $-4.23 0.00
2020-03-31 30.58 $-4.66 0.00
2019-12-31 21.00 $-3.63 0.00
2019-09-30 23.88 $-3.74 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.560B $0.090B
Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00